Design Therapeutics, Inc. – NASDAQ:DSGN
Design Therapeutics stock price today
$5.17
-1.08
-17.28%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Design Therapeutics stock price monthly change
+43.35%
month
Design Therapeutics stock price quarterly change
+43.35%
quarter
Design Therapeutics stock price yearly change
+131.48%
year
Design Therapeutics key metrics
Market Cap | 348.21M |
Enterprise value | 259.86M |
P/E | -4.44 |
EV/Sales | N/A |
EV/EBITDA | -4.13 |
Price/Sales | N/A |
Price/Book | 0.86 |
PEG ratio | 0.09 |
EPS | -1.05 |
Revenue | N/A |
EBITDA | -70.52M |
Income | -58.67M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeDesign Therapeutics stock price history
Design Therapeutics stock forecast
Design Therapeutics financial statements
| Jun 2023 | 0 | -19.93M | |
|---|---|---|---|
| Sep 2023 | 0 | -15.78M | |
| Dec 2023 | 838K | -11.84M | -1413.13% |
| Mar 2024 | 0 | -11.10M |
| Sep 2025 | 0 | -23.51M | |
|---|---|---|---|
| Oct 2025 | 0 | -20.90M | |
| Dec 2025 | 0 | -24.07M | |
| Dec 2025 | 0 | -20.90M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 311630000 | 14.83M | 4.76% |
|---|---|---|---|
| Sep 2023 | 299869000 | 14.91M | 4.97% |
| Dec 2023 | 289643000 | 11.95M | 4.13% |
| Mar 2024 | 278793000 | 9.23M | 3.31% |
| Jun 2023 | -13.80M | 11.98M | 210 |
|---|---|---|---|
| Sep 2023 | -14.53M | 15.26M | 13 |
| Dec 2023 | -12.79M | 5.55M | 501 |
| Mar 2024 | -12.43M | 20.61M | 20K |
Design Therapeutics alternative data
| Aug 2023 | 64 |
|---|---|
| Sep 2023 | 68 |
| Oct 2023 | 68 |
| Nov 2023 | 68 |
| Dec 2023 | 57 |
| Jan 2024 | 57 |
| Feb 2024 | 57 |
| Mar 2024 | 57 |
| Apr 2024 | 57 |
| May 2024 | 57 |
| Jun 2024 | 57 |
| Jul 2024 | 57 |
Design Therapeutics other data
24.85%
-47.52%
of DSGN is owned by hedge funds
51
-29
13.84M
-26.52M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 28265 | 0 |
| Aug 2024 | 0 | 814874 |
| Dec 2024 | 0 | 3806 |
| Patent |
|---|
Application Filling date: 9 May 2019 Issue date: 16 Sep 2021 |
Application Filling date: 19 Apr 2019 Issue date: 16 Sep 2021 |
Application Filling date: 22 May 2019 Issue date: 5 Aug 2021 |
Application Filling date: 22 May 2019 Issue date: 29 Jul 2021 |
| Quarter | Transcript |
|---|---|
| Q4 2023 19 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. JoĂŁo Siffert (1963) Pres, Chief Executive Officer & Director | $491,670 |
| Dr. Sean Jeffries Ph.D. (1980) Chief Operating Officer | $343,330 |
-
What's the price of Design Therapeutics stock today?
One share of Design Therapeutics stock can currently be purchased for approximately $5.17.
-
When is Design Therapeutics's next earnings date?
Unfortunately, Design Therapeutics's (DSGN) next earnings date is currently unknown.
-
Does Design Therapeutics pay dividends?
No, Design Therapeutics does not pay dividends.
-
How much money does Design Therapeutics make?
Design Therapeutics has a market capitalization of 348.21M.
-
What is Design Therapeutics's stock symbol?
Design Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "DSGN".
-
What is Design Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Design Therapeutics?
Shares of Design Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Design Therapeutics's key executives?
Design Therapeutics's management team includes the following people:
- Dr. JoĂŁo Siffert Pres, Chief Executive Officer & Director(age: 62, pay: $491,670)
- Dr. Sean Jeffries Ph.D. Chief Operating Officer(age: 45, pay: $343,330)
-
How many employees does Design Therapeutics have?
As Jul 2024, Design Therapeutics employs 57 workers.
-
When Design Therapeutics went public?
Design Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 29 Mar 2021.
-
What is Design Therapeutics's official website?
The official website for Design Therapeutics is designtx.com.
-
Where are Design Therapeutics's headquarters?
Design Therapeutics is headquartered at 6005 Hidden Valley Road, Carlsbad, CA.
-
How can i contact Design Therapeutics?
Design Therapeutics's mailing address is 6005 Hidden Valley Road, Carlsbad, CA and company can be reached via phone at 858 293 4900.
Design Therapeutics company profile:
Design Therapeutics, Inc.
designtx.comExchange:
NASDAQ
Full time employees:
54
Industry:
Biotechnology
Sector:
Healthcare
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
6005 Hidden Valley Road
Carlsbad, CA 92011
Carlsbad, CA 92011
CIK: 0001807120
ISIN: US25056L1035
CUSIP: 25056L103
